Liao Caiyun, Golden William Christopher, Anderson Jean R, Coleman Jenell S
1 Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine , Baltimore, Maryland.
2 Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland.
AIDS Patient Care STDS. 2017 Jan;31(1):20-26. doi: 10.1089/apc.2016.0204. Epub 2016 Dec 12.
HIV testing is an effective intervention that is used for reducing perinatal HIV transmission. Centers for Disease Control and Prevention recommends a second HIV test during the third trimester of pregnancy for women in settings with an elevated HIV incidence (≥17 cases per 100,000 person-years). We conducted a retrospective cohort study at a single hospital in Baltimore, Maryland, to determine whether a second HIV test was done and to compare HIV retesting with mandated syphilis retesting. Of women who delivered at this hospital, 98.8% received prenatal care. Descriptive, bivariate, and multivariable analyses were performed. Among 1632 women, mean age was 27.6 years (standard deviation: 6.3), 59.6% were black, and 55.5% were single. HIV retesting was done in 28.4% of women, which was significantly less often compared with the state-mandated syphilis retesting (78.7%, p < 0.001). The odds of having an HIV retest were 15 times higher among women who received prenatal care at a teaching clinic [adjusted odds ratio (aOR): 15.58; 95% confidence interval (CI): 11.12-21.81], and they were lower among women with private insurance (aOR: 0.54, 95% CI: 0.34-0.86). The odds of having a syphilis retest were twice as high among women who received prenatal care at a faculty practice (aOR: 2.17; 95% CI: 1.53-3.09), and they were lower among women with private insurance (aOR: 0.61, 95% CI: 0.43-0.88). Emphasizing an "opt-out" HIV retesting approach through state laws may minimize risk perception, and this is one strategy that can be considered in areas of high HIV incidence to reach the goal of eliminating perinatal HIV transmission in the United States.
艾滋病毒检测是一种用于减少围产期艾滋病毒传播的有效干预措施。美国疾病控制与预防中心建议,在艾滋病毒发病率较高(≥每10万人年17例)的地区,对孕期女性在孕晚期进行第二次艾滋病毒检测。我们在马里兰州巴尔的摩的一家医院开展了一项回顾性队列研究,以确定是否进行了第二次艾滋病毒检测,并将艾滋病毒复测与法定梅毒复测进行比较。在这家医院分娩的女性中,98.8%接受了产前护理。进行了描述性、双变量和多变量分析。在1632名女性中,平均年龄为27.6岁(标准差:6.3),59.6%为黑人,55.5%为单身。28.4%的女性进行了艾滋病毒复测,与法定梅毒复测相比(78.7%),复测频率显著更低(p<0.001)。在教学诊所接受产前护理的女性中,进行艾滋病毒复测的几率高出15倍[调整后的优势比(aOR):15.58;95%置信区间(CI):11.12 - 21.81],而在有私人保险的女性中几率较低(aOR:0.54,95%CI:0.34 - 0.86)。在教职工诊所接受产前护理的女性中,进行梅毒复测的几率高出两倍(aOR:2.17;95%CI:1.53 - 3.09),而在有私人保险的女性中几率较低(aOR:0.61,95%CI:0.43 - 0.88)。通过州法律强调“退出式”艾滋病毒复测方法可能会降低风险认知,这是在艾滋病毒高发地区为实现美国消除围产期艾滋病毒传播目标可考虑的一种策略。